SWX:GALEHealthcare
Galenica (SWX:GALE) Just Gave Investors Something To Think About
Galenica (SWX:GALE) is back in focus after its half year 2026 results showed higher sales and revenue alongside lower net income, while the company reaffirmed its 2026 guidance for net sales and EBIT growth.
See our latest analysis for Galenica.
Galenica’s recent half year results and confirmed 2026 guidance come after a share price that is down 17.6% year to date to CHF81.1, while the 5 year total shareholder return of 31.1% points to a stronger longer term picture. Short term share price...